484 related articles for article (PubMed ID: 28685353)
1. Peginterferon beta-1a reduces the evolution of MRI lesions to black holes in patients with RRMS: a post hoc analysis from the ADVANCE study.
Arnold DL; You X; Castrillo-Viguera C
J Neurol; 2017 Aug; 264(8):1728-1734. PubMed ID: 28685353
[TBL] [Abstract][Full Text] [Related]
2. Effect of peginterferon beta-1a on MRI measures and achieving no evidence of disease activity: results from a randomized controlled trial in relapsing-remitting multiple sclerosis.
Arnold DL; Calabresi PA; Kieseier BC; Sheikh SI; Deykin A; Zhu Y; Liu S; You X; Sperling B; Hung S
BMC Neurol; 2014 Dec; 14():240. PubMed ID: 25551571
[TBL] [Abstract][Full Text] [Related]
3. Peginterferon beta-1a improves MRI measures and increases the proportion of patients with no evidence of disease activity in relapsing-remitting multiple sclerosis: 2-year results from the ADVANCE randomized controlled trial.
Arnold DL; Calabresi PA; Kieseier BC; Liu S; You X; Fiore D; Hung S
BMC Neurol; 2017 Feb; 17(1):29. PubMed ID: 28183276
[TBL] [Abstract][Full Text] [Related]
4. Early treatment responses to peginterferon beta-1a are associated with longer-term clinical outcomes in patients with relapsing-remitting multiple sclerosis: Subgroup analyses of ADVANCE and ATTAIN.
Newsome SD; Scott TF; Arnold DL; Altincatal A; Naylor ML
Mult Scler Relat Disord; 2022 Jan; 57():103367. PubMed ID: 35158473
[TBL] [Abstract][Full Text] [Related]
5. Subgroup and sensitivity analyses of annualized relapse rate over 2 years in the ADVANCE trial of peginterferon beta-1a in patients with relapsing-remitting multiple sclerosis.
Newsome SD; Kieseier BC; Arnold DL; Shang S; Liu S; Hung S; Sabatella G
J Neurol; 2016 Sep; 263(9):1778-87. PubMed ID: 27314959
[TBL] [Abstract][Full Text] [Related]
6. Peginterferon beta-1a in multiple sclerosis: 2-year results from ADVANCE.
Kieseier BC; Arnold DL; Balcer LJ; Boyko AA; Pelletier J; Liu S; Zhu Y; Seddighzadeh A; Hung S; Deykin A; Sheikh SI; Calabresi PA
Mult Scler; 2015 Jul; 21(8):1025-35. PubMed ID: 25432952
[TBL] [Abstract][Full Text] [Related]
7. Impact of peginterferon beta-1a and disease factors on quality of life in multiple sclerosis.
Newsome SD; Guo S; Altincatal A; Proskorovsky I; Kinter E; Phillips G; You X; Sabatella G
Mult Scler Relat Disord; 2015 Jul; 4(4):350-7. PubMed ID: 26195056
[TBL] [Abstract][Full Text] [Related]
8. Pegylated interferon β-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study.
Calabresi PA; Kieseier BC; Arnold DL; Balcer LJ; Boyko A; Pelletier J; Liu S; Zhu Y; Seddighzadeh A; Hung S; Deykin A;
Lancet Neurol; 2014 Jul; 13(7):657-65. PubMed ID: 24794721
[TBL] [Abstract][Full Text] [Related]
9. Matching-adjusted comparisons demonstrate better clinical outcomes with SC peginterferon beta-1a every two weeks than with SC interferon beta-1a three times per week.
Coyle PK; Shang S; Xiao Z; Dong Q; Castrillo-Viguera C
Mult Scler Relat Disord; 2018 May; 22():134-138. PubMed ID: 29679749
[TBL] [Abstract][Full Text] [Related]
10. Analysis of peginterferon β-1a exposure and Gd-enhanced lesion or T2 lesion response in relapsing-remitting multiple sclerosis patients.
Hang Y; Hu X; Zhang J; Liu S; Deykin A; Nestorov I
J Pharmacokinet Pharmacodyn; 2016 Aug; 43(4):371-83. PubMed ID: 27299457
[TBL] [Abstract][Full Text] [Related]
11. Daclizumab high-yield process reduced the evolution of new gadolinium-enhancing lesions to T1 black holes in patients with relapsing-remitting multiple sclerosis.
Radue EW; Sprenger T; Vollmer T; Giovannoni G; Gold R; Havrdova E; Selmaj K; Stefoski D; You X; Elkins J
Eur J Neurol; 2016 Feb; 23(2):412-5. PubMed ID: 26806217
[TBL] [Abstract][Full Text] [Related]
12. Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial.
Togha M; Karvigh SA; Nabavi M; Moghadam NB; Harirchian MH; Sahraian MA; Enzevaei A; Nourian A; Ghanaati H; Firouznia K; Jannati A; Shekiba M
Mult Scler; 2010 Jul; 16(7):848-54. PubMed ID: 20488825
[TBL] [Abstract][Full Text] [Related]
13. [Role of peginterferon-β-1a in the therapy of multiplex sclerosis].
Simó M; Iljicsov A
Ideggyogy Sz; 2017 Nov; 70(11-12):365-368. PubMed ID: 29870644
[TBL] [Abstract][Full Text] [Related]
14. Peginterferon beta-1a: a review of its use in patients with relapsing-remitting multiple sclerosis.
Hoy SM
CNS Drugs; 2015 Feb; 29(2):171-9. PubMed ID: 25666445
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness analysis of peginterferon beta-1a compared with interferon beta-1a and glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis in the United States.
Hernandez L; Guo S; Kinter E; Fay M
J Med Econ; 2016 Jul; 19(7):684-95. PubMed ID: 26947984
[TBL] [Abstract][Full Text] [Related]
16. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial.
Mikol DD; Barkhof F; Chang P; Coyle PK; Jeffery DR; Schwid SR; Stubinski B; Uitdehaag B;
Lancet Neurol; 2008 Oct; 7(10):903-14. PubMed ID: 18789766
[TBL] [Abstract][Full Text] [Related]
17. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
Hauser SL; Bar-Or A; Comi G; Giovannoni G; Hartung HP; Hemmer B; Lublin F; Montalban X; Rammohan KW; Selmaj K; Traboulsee A; Wolinsky JS; Arnold DL; Klingelschmitt G; Masterman D; Fontoura P; Belachew S; Chin P; Mairon N; Garren H; Kappos L;
N Engl J Med; 2017 Jan; 376(3):221-234. PubMed ID: 28002679
[TBL] [Abstract][Full Text] [Related]
18. Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon β-1a in MS.
Arnold DL; Fisher E; Brinar VV; Cohen JA; Coles AJ; Giovannoni G; Hartung HP; Havrdova E; Selmaj KW; Stojanovic M; Weiner HL; Lake SL; Margolin DH; Thomas DR; Panzara MA; Compston DA;
Neurology; 2016 Oct; 87(14):1464-1472. PubMed ID: 27590291
[TBL] [Abstract][Full Text] [Related]
19. Matching-adjusted comparisons demonstrate better clinical outcomes in patients with relapsing multiple sclerosis treated with peginterferon beta-1a than with teriflunomide.
Newsome SD; Mokliatchouk O; Castrillo-Viguera C; Naylor ML
Mult Scler Relat Disord; 2020 May; 40():101954. PubMed ID: 32078948
[TBL] [Abstract][Full Text] [Related]
20. Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis.
Barkhof F; Kappos L; Wolinsky JS; Li DKB; Bar-Or A; Hartung HP; Belachew S; Han J; Julian L; Sauter A; Napieralski J; Koendgen H; Hauser SL
Neurology; 2019 Nov; 93(19):e1778-e1786. PubMed ID: 31484710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]